ResearchA pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma
ResearchEffectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
ResearchImpact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
ResearchLesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma
ResearchInternational Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
ResearchEpidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era
ResearchDynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model
ResearchLenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool
ResearchMAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma
ResearchT-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
ResearchPopulation Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity After Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
ResearchBeyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma
ResearchModeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone